Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | APEX1 | P27695 | 3/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | ACHE | P22303 | 2/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.53 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029262 | 1.00 | MEN1 (0.69) | MEN1KMT2ALMNAAPEX1NFKB1 | |
| SCHEMBL27892330 | 1.00 | MEN1 (0.69) | MEN1KMT2ALMNAAPEX1NFKB1 | |
| SCHEMBL10596619 | 1.00 | MEN1 (0.69) | MEN1KMT2ALMNAAPEX1NFKB1 | |
| SCHEMBL10596463 | 1.00 | MEN1 (0.69) | MEN1KMT2ALMNAAPEX1NFKB1 | |
| SCHEMBL15055195 | 1.00 | MEN1 (0.69) | MEN1KMT2ALMNAAPEX1NFKB1 | |
| SCHEMBL10597103 | 1.00 | MEN1 (0.69) | MEN1KMT2ALMNAAPEX1NFKB1 | |
| Hydrochloric Acid SCHEMBL2042679 | 0.97 | APEX1 (0.71) | MEN1KMT2ALMNAAPEX1NFKB1 | |
| Fluoride Ion SCHEMBL9761143 | 0.97 | MEN1 (0.65) | MEN1KMT2ALMNAAPEX1NFKB1 | |
| Bromide SCHEMBL2355631 | 0.97 | MEN1 (0.71) | MEN1KMT2ALMNAAPEX1NFKB1 | |
| Bromide SCHEMBL28865464 | 0.97 | MEN1 (0.71) | MEN1KMT2ALMNAAPEX1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592458-B2 | Alpha7 nicotinic receptor selective ligands | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-11-26 | — | — | US | claimed |
| US-20120094943-A1 | ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-04-19 | — | — | US | claimed |
| US-8093269-B2 | Alpha 7 nicotinic receptor selective ligands | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2012-01-10 | — | — | US | claimed |
| US-20090215705-A1 | Alpha 7 Nicotinic Receptor Selective Ligands | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-08-27 | — | — | US | claimed |
| EP-1891036-A1 | ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS | University of Florida Research Foundation, Inc. (US) | 2008-02-27 | — | — | EP | claimed |
| WO-2006133303-A1 | ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-12-14 | — | — | WO | claimed |
| EP-0122151-B1 | PRODUCTION OF PRIMARY OR SECONDARY ALCOHOL DERIVATIVES OF PHOSPHOLIPIDS BY THE ENZYMATIC TECHNIQUE | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1989-02-15 | — | — | EP | claimed |
| US-8592458-B2 | Alpha7 nicotinic receptor selective ligands | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120094943-A1 | ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8093269-B2 | Alpha 7 nicotinic receptor selective ligands | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100292439-A1 | Use of Functionalized Onium Salts for Peptide Synthesis | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE` (FR) | 2010-11-18 | — | — | US | disclosed |
| US-20090215705-A1 | Alpha 7 Nicotinic Receptor Selective Ligands | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| EP-1891036-A1 | ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS | University of Florida Research Foundation, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006133303-A1 | ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| US-20020173489-A1 | COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTER E.V. (DE) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292439-A1 | Use of Functionalized Onium Salts for Peptide Synthesis | NPY1R, CNKSR1, NPBWR1 | MEN1 1628/4885KMT2A 4277/4885LMNA 3555/4885 |
| US-20090215705-A1 | Alpha 7 Nicotinic Receptor Selective Ligands | CHRNA7, CHRNA10, CHRNA5 | MEN1 3799/4885KMT2A 2858/4885LMNA 4208/4885 |
| US-20020173489-A1 | COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS | PHOSPHO1, PLCG2, PPIP5K2 | MEN1 542/4885KMT2A 3584/4885LMNA 3263/4885 |
| US-20120094943-A1 | ALPHA 7 NICOTINIC RECEPTOR SELECTIVE LIGANDS | CHRNA7, CHRNA10, CHRNA5 | MEN1 3799/4885KMT2A 2858/4885LMNA 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.